Monte Rosa Therapeutics

News

Novartis agrees $5.7bn degrader deal with Monte Rosa

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year.

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

News

Roche sticks with molecular glue, partnering Monte Rosa

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that i

Novartis agrees $5.7bn degrader deal with Monte Rosa

Novartis pays $150m upfront for Monte Rosa degrader drug

Roche sticks with molecular glue, partnering Monte Rosa

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Monte Rosa Therapeutics

Editor's Picks